Skip to content
10-Q

Quarterly Report

Asterias Biotherapeutics, Inc.

0001140361-17-032095

← back to feed
Filed
Aug 14, 2017 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Cash And Equivalents Q2 2017 · Jun 30, 2017 $11.88M
Cash And Equivalents Q2 2017 · Dec 31, 2016 $19.8M
Cash And Equivalents Q2 2017 · Jun 30, 2016 $21.47M
Cash And Equivalents Q2 2017 · Dec 31, 2015 $11.18M
Stockholders Equity Q2 2017 · Jun 30, 2017 $36.72M
Stockholders Equity Q2 2017 · Dec 31, 2016 $42.03M
Current Liabilities Q2 2017 · Jun 30, 2017 $2.02M
Current Liabilities Q2 2017 · Dec 31, 2016 $6.05M
Total Liabilities Q2 2017 · Jun 30, 2017 $11.85M
Total Liabilities Q2 2017 · Dec 31, 2016 $18.98M
Current Assets Q2 2017 · Jun 30, 2017 $26.37M
Current Assets Q2 2017 · Dec 31, 2016 $36.99M
Total Assets Q2 2017 · Jun 30, 2017 $48.56M
Total Assets Q2 2017 · Dec 31, 2016 $61.01M
Capex Q2 2017 · Jun 30, 2016 $499K
Operating Cash Flow Q2 2017 · Jun 30, 2016 −$10.01M
Sga Expense Q2 2017 · Jun 30, 2016 $2.58M
Sga Expense Q2 2017 · Jun 30, 2016 $8.87M
Rd Expense Q2 2017 · Jun 30, 2016 $6.02M
Rd Expense Q2 2017 · Jun 30, 2016 $12.36M
Net Income Q2 2017 · Jun 30, 2016 −$5.16M
Net Income Q2 2017 · Jun 30, 2016 −$15.5M
Operating Income Q2 2017 · Jun 30, 2016 −$7.07M
Operating Income Q2 2017 · Jun 30, 2016 −$18.17M
Gross Profit Q2 2017 · Jun 30, 2016 $1.53M
Gross Profit Q2 2017 · Jun 30, 2016 $3.07M
Cost Of Revenue Q2 2017 · Jun 30, 2016 $6K
Cost Of Revenue Q2 2017 · Jun 30, 2016 $59K